quemliclustat + zimberelimab + docetaxel

A combination therapy comprised of **quemliclustat** (a small molecule inhibitor of CD73), **zimberelimab** (a monoclonal antibody checkpoint inhibitor targeting PD-1), and **docetaxel** (a microtubule-stabilizing chemotherapeutic agent). Quemliclustat targets CD73 to block adenosine production in the tumor microenvironment, potentially enhancing anti-tumor immune activity. Zimberelimab, an anti-PD-1 antibody, further boosts immunotherapy efficacy by blocking the interaction between PD-1 and its ligands, thereby reinvigorating T-cell response against tumors. Docetaxel stabilizes microtubules and prevents their depolymerization, leading to cell cycle arrest and apoptosis in cancer cells. The combination is under investigation for its synergistic anti-tumor and immunomodulatory effects, primarily in pancreatic cancer and potentially other solid tumors[3][5][6][2][4].

Other names

quemliclustat + zimberelimab + docetaxel